Study to Evaluate the Efficacy, Safety and Pharmacokinetics of PT001, PT003, and PT005 Following Chronic Dosing (7 Days) in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)

NCT01085045 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

118

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Obstructive Pulmonary Disease

Interventions

DRUG: PT003 MDI
DRUG: PT005 MDI
DRUG: Placebo MDI
DRUG: Tiotropium bromide 18 μg (Spiriva Handihaler®)
DRUG: Formoterol Fumarate 12 μg (Foradil® Aerolizer®)
DRUG: PT001 MDI

Sponsor

Pearl Therapeutics, Inc.